Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: a review of studies and experience at The Johns Hopkins Hospital, 1991-2003.
In 1991 a multidisciplinary group consisting of surgeons, radiation oncologists, medical oncologists, pathologists, research nurses, and laboratory scientists was organized at the Johns Hopkins Hospital to accelerate progress in understanding the clinical and basic biology of pancreatic carcinoma and to develop research protocols aimed at improving clinical outcomes. This article discusses the studies, data, and conclusions generated to date, in some cases preliminarily, for the clinical trials and algorithms the Johns Hopkins team applied to the postoperative adjuvant management of periampullary pancreatic and nonpancreatic periampullary adenocarcinomas during the interval 1991 to 2003.
Abrams
Ross A
RA
Department of Radiation Oncology, Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612, USA. Ross_A_Abrams@Rush.edu
Yeo
Charles J
CJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000465:Algorithms; D014670:Ampulla of Vater / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015142:Baltimore; D017024:Chemotherapy, Adjuvant; D017321:Clinical Trials, Phase I as Topic; D003131:Combined Modality Therapy; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D016577:Pancreaticoduodenectomy / Q000379:methods; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome